528 related articles for article (PubMed ID: 27098382)
1. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
Talotta R; Atzeni F; Sarzi Puttini P
BMC Pharmacol Toxicol; 2016 Apr; 17():17. PubMed ID: 27098382
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
4. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.
Laohapand C; Arromdee E; Tanwandee T
Hepatol Int; 2015 Apr; 9(2):202-8. PubMed ID: 25788188
[TBL] [Abstract][Full Text] [Related]
5. Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection.
Padovan M; Filippini M; Tincani A; Lanciano E; Bruschi E; Epis O; Garau P; Mathieu A; Celletti E; Giani L; Tomietto P; Atzeni F; Sarzi Puttini P; Zuliani F; De Vita S; Trotta F; Grilli A; Puoti M; Govoni M
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):738-43. PubMed ID: 26555747
[TBL] [Abstract][Full Text] [Related]
6. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
Lee YH; Bae SC; Song GG
Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital.
Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
Arthritis Res Ther; 2019 Nov; 21(1):255. PubMed ID: 31779676
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
Watanabe T; Fukae J; Fukaya S; Sawamukai N; Isobe M; Matsuhashi M; Shimizu M; Akikawa K; Tanimura K; Atsumi T; Koike T
Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649
[TBL] [Abstract][Full Text] [Related]
11. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
Chen LF; Mo YQ; Jing J; Ma JD; Zheng DH; Dai L
Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
[TBL] [Abstract][Full Text] [Related]
12. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
Giardina AR; Ferraro D; Ciccia F; Ferrante A; Di Stefano R; Craxì A; Triolo G
Clin Exp Rheumatol; 2013; 31(1):25-30. PubMed ID: 22935442
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
Nakamura J; Nagashima T; Nagatani K; Yoshio T; Iwamoto M; Minota S
Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305
[TBL] [Abstract][Full Text] [Related]
14. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment.
Kuo MH; Tseng CW; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
Dig Dis Sci; 2021 Nov; 66(11):4026-4034. PubMed ID: 33387124
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.
Wang ST; Tseng CW; Hsu CW; Tung CH; Huang KY; Lu MC; Lai NS
Int J Rheum Dis; 2021 Nov; 24(11):1362-1369. PubMed ID: 34506078
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reactivation during belatacept treatment after kidney transplantation.
Cambier ML; Canestri A; Lependeven C; Peltier J; Mesnard L; Dahan K
Transpl Infect Dis; 2019 Dec; 21(6):e13170. PubMed ID: 31505095
[TBL] [Abstract][Full Text] [Related]
17. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
Yaşar DG; Suyanı E; Özenirler S; Sucak GT
Transplant Proc; 2013 Mar; 45(2):833-4. PubMed ID: 23498831
[TBL] [Abstract][Full Text] [Related]
18. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
[TBL] [Abstract][Full Text] [Related]
19. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
Kuo MH; Tseng CW; Ko PH; Wang ST; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
Liver Int; 2024 Feb; 44(2):497-507. PubMed ID: 38010984
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients.
Urata Y; Uesato R; Tanaka D; Kowatari K; Nitobe T; Nakamura Y; Motomura S
Mod Rheumatol; 2011 Feb; 21(1):16-23. PubMed ID: 20668905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]